{
    "clinical_study": {
        "@rank": "110979", 
        "acronym": "IIL INFL09", 
        "arm_group": {
            "arm_group_label": "Rituximab - Bendamustine (RB)", 
            "arm_group_type": "Experimental", 
            "description": "1 arm: Rituximab - Bendamustine (RB)\n1 arm for all patients"
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, multicenter phase II trial designed to determine efficacy and safety\n      of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with\n      advanced untreated Indolent non Follicular non-Hodgkin Lymphomas (INFL)."
        }, 
        "brief_title": "A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Indolent Non-follicular", 
            "Non-Hodgkin's Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, multicenter phase II trial designed to determine efficacy and safety\n      of a chemoimmunotherapy with the combination of Bendamustine + Rituximab in patients with\n      advanced untreated Indolent non Follicular non-Hodgkin Lymphomas (INFL).\n\n      The study includes and induction phase and a consolidation phase."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Understand and voluntarily sign an informed consent form\n\n          2. Histological (bone marrow or lymph nodes biopsy) proven diagnosis of B-cell CD20-\n             positive non-follicular NHL according to REAL/WHO Classification:\n\n             i. small lymphocytic lymphoma-SLL (bone marrow or lymph nodes biopsy ii.\n             lymphoplasmacytic/citoid lymphoma/ Waldenstrom macroglobulinemia(bone marrow or\n             lymph nodes biopsy) iii. nodal marginal zone lymphoma (lymph nodes biopsy)\n\n          3. Untreated patients\n\n          4. Stage III or IV or stage II with  more than three involved sites\n\n          5. Presence of at least one of the following criteria for the definition of active\n             disease:\n\n               1. Systemic symptoms\n\n               2. Hemoglobin less than 10 g/dL (due to lymphoma)\n\n               3. Platelets less than 100 x 10 9/L (due to lymphoma)\n\n               4. Diffuse bone marrow infiltrate\n\n               5. Lymphocyte doubling time less than 12 months (in leukemic cases)\n\n               6. Bulky disease (>7 cm)\n\n          6. Aged  18 - 75    Life expectancy >6 months\n\n          7. ECOG performance status 0-2\n\n          8. LVEF \u226545% or FS \u226537%\n\n          9. ANC \u22651 x 10 9/l and Platelets count \u226575 x 10 9/l, unless due to bone marrow\n             involvement by follicular lymphoma\n\n         10. Creatinine up to 1.5 x ULN\n\n         11. Conjugated bilirubin up to 2 x ULN\n\n         12. Alkaline phosphatase and transaminases up to 2 x ULN\n\n         13. Written informed content\n\n        Exclusion Criteria:\n\n          1. Patients with diagnosis of marginal zone lymphoma of splenic or MALT origin\n\n          2. Patients with diagnosis of typical Chronic Lymphocytic Leukemia (CLL)\n\n          3. Men not agreeing to take adequate contraceptive precautions during and for at least 6\n             months after cessation of therapy\n\n          4. History of other malignancies within 3 years prior to study entry except for:\n             adequately treated carcinoma in situ of the cervix; basal or squamous cell skin\n             cancer; low grade, early stage, localized prostate cancer treated surgically with\n             curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with\n             curative intent\n\n          5. Medical condition requiring long term use (>1 months) of systemic corticosteroids\n\n          6. Active bacterial, viral, or fungal infection requiring systemic therapy\n\n          7. Concurrent medical condition which might exclude administration of therapy\n\n          8. Cardiac insufficiency (NYHA grade III/IV)\n\n          9. Myocardial infarction within 6 months of entry on study\n\n         10. Severe chronic obstructive pulmonary disease with hypoxemia\n\n         11. Severe diabetes mellitus difficult to control with adequate insulin therapy\n\n         12. Hypertension that is difficult to control\n\n         13. Impaired renal function with creatinine clearance <30 ml/min\n\n         14. HIV positivity\n\n         15. HBV positivity with the exception of patients HbsAg negative and Ab anti-Hbcore\n             positive(these patientes need to receive prophylaxis with Lamivudine)\n\n         16. HCV positivity with the exception of patients with HCV RNA negative.\n\n         17. CNS involvement by lymphoma\n\n         18. Participation at the same time in another study in with investiogational drugs are\n             used\n\n         19. Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins\n\n         20. Any other co-existing medical or psychological condition that would preclude\n             participation in the study or compromise ability to give informed consent\n\n         21. Women in pregnancy or breastfeeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "73", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929265", 
            "org_study_id": "IIL INFL09"
        }, 
        "intervention": {
            "arm_group_label": "Rituximab - Bendamustine (RB)", 
            "description": "INDUCTION  PHASE\nRituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):\nRituximab: 375 mg/sqm iv, day 1*\nBendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice\nRepeat cycles every 28 days for a total of 4 cycles\n*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.\nCONSOLIDATION  PHASE\nRituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):\nRituximab: 375 mg/sqm iv day 1\nBendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice\nRituximab  two  monthly doses\nRituximab: 375 mg/sqm   iv  week   24  and  28", 
            "intervention_name": "Bendamustine", 
            "intervention_type": "Drug", 
            "other_name": "RIBOMUSTIN"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Bendamustine", 
                "Rituximab", 
                "Nitrogen Mustard Compounds"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "INFL", 
            "Indolent non-follicular", 
            "untreated INFL"
        ], 
        "lastchanged_date": "August 22, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Alessandria", 
                        "country": "Italy", 
                        "state": "AL", 
                        "zip": "15121"
                    }, 
                    "name": "SC Ematologia - AO SS. Antonio e Biagio e C. Arrigo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Asti", 
                        "country": "Italy", 
                        "state": "AT"
                    }, 
                    "name": "Medicina interna - ASL AL Osp. Cardinal Massaia"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy", 
                        "state": "BA"
                    }, 
                    "name": "Ematologia Azienda Ospedaliera Policlinico"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brescia", 
                        "country": "Italy", 
                        "state": "BS"
                    }, 
                    "name": "SC Ematologia Spedali Civili"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bolzano", 
                        "country": "Italy", 
                        "state": "BZ"
                    }, 
                    "name": "Divisione di Ematologia e Trapianti, Ospedale San Maurizio"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Giovanni Rotondo", 
                        "country": "Italy", 
                        "state": "Foggia"
                    }, 
                    "name": "Divisione di Ematologia, Centro Trapianto di Cellule Staminali"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "state": "GE"
                    }, 
                    "name": "Divisione Ematologia I , Ospedale San Martino"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Messina", 
                        "country": "Italy", 
                        "state": "ME"
                    }, 
                    "name": "S.C. Ematologia Azienda Ospedaliera Papardo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rozzano", 
                        "country": "Italy", 
                        "state": "Milano"
                    }, 
                    "name": "Divisione di Oncologia Medica ed Ematologia, Istituto Clinico Humanitas"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI"
                    }, 
                    "name": "Divisione di Ematologia Ospedale Niguarda"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Modena", 
                        "country": "Italy", 
                        "state": "MO"
                    }, 
                    "name": "Centro Oncologico Modenese"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy", 
                        "state": "PA"
                    }, 
                    "name": "Ematologia Azienda Ospedaliero Universitaria Paolo Giaccone"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy", 
                        "state": "PA"
                    }, 
                    "name": "Divisione di Ematologia Azienda Ospedali Riuniti Villa Sofia Cervello"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aviano", 
                        "country": "Italy", 
                        "state": "PN"
                    }, 
                    "name": "Div. Oncologia Medica - CRO, Centro di Riferimento Oncologico"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy"
                    }, 
                    "name": "UOC Ematologia 1/CTMO, Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy"
                    }, 
                    "name": "Oncoematologia Istituto Pascale"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novara", 
                        "country": "Italy"
                    }, 
                    "name": "S.C.D.U Ematologia Azienda Ospedaliero Universitaria Maggiore"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy"
                    }, 
                    "name": "UO Ematologia Universit\u00e0 - Policlinico San Matteo"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pescara", 
                        "country": "Italy"
                    }, 
                    "name": "Ematologia Ospedale Santo Spirito"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Piacenza", 
                        "country": "Italy"
                    }, 
                    "name": "UOA Ematologia, Ospedale Civile Ospedale G. da Saliceto"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reggio Calabria", 
                        "country": "Italy"
                    }, 
                    "name": "Div. Ematologia AO Bianchi Melacrino Morelli"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Reggio Emilia", 
                        "country": "Italy"
                    }, 
                    "name": "Ematologia, Azienda Ospedaliera Arcispedale \"S.Maria Nuova\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Ematologia, Universit\u00e0 \"La Sapienza\""
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Siena", 
                        "country": "Italy"
                    }, 
                    "name": "Clinica Ematologia Policlino Le Scotte"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Terni", 
                        "country": "Italy"
                    }, 
                    "name": "Struttura Complessa di Onco-Ematologia Azienda Ospedaliera S.Maria"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy"
                    }, 
                    "name": "UO Ematologia 2 - Citt\u00e0 della Salute e della Scienza"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy"
                    }, 
                    "name": "UO Ematologia 1 - Citt\u00e0 della Salute e della Scienza"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Udine", 
                        "country": "Italy"
                    }, 
                    "name": "Clinica Ematologica e Unit\u00e0 di Terapie Cellulari 'Carlo Melzi' AOU S. Maria della Misericordia"
                }
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma", 
        "overall_official": {
            "affiliation": "UOC Ematologia 1/CTMO, Fondazione IRCCS C\u00e0 Granda Ospedale Maggiore Policlinico", 
            "last_name": "Luca Baldini, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluated at the end of treatment", 
            "measure": "Complete remission rate (CR)", 
            "safety_issue": "No", 
            "time_frame": "5 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929265"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluated during and at the end of treatment. Percentage of patients with adverse, hematological and non-hematological toxic events", 
                "measure": "Safety analysis", 
                "safety_issue": "Yes", 
                "time_frame": "5 months"
            }, 
            {
                "description": "Evaluated at the end of treatment. Complete plus partial remission.", 
                "measure": "Overall response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "5 months"
            }, 
            {
                "description": "Dead for any causes after diagnosis. Evaluated by means of Kaplan-Meier method.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "at 2 years"
            }, 
            {
                "description": "Progression, relapse or dead for any causes after diagnosis. Evaluated by means of Kaplan-Meier method.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "at 2 years"
            }, 
            {
                "description": "Relapse or dead for any causes from the end of treatment, for patients in CR after B+R. Evaluated by means of Kaplan-Meier method.", 
                "measure": "Disease free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "at 2 years"
            }
        ], 
        "source": "Fondazione Italiana Linfomi ONLUS", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fondazione Italiana Linfomi ONLUS", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2010"
    }
}